-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Head to Head Comparison: VG Life Sciences (OTCMKTS:VGLS) Vs. Longeveron (NASDAQ:LGVN)
Head to Head Comparison: VG Life Sciences (OTCMKTS:VGLS) Vs. Longeveron (NASDAQ:LGVN)
Longeveron (NASDAQ:LGVN – Get Rating) and VG Life Sciences (OTCMKTS:VGLS – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.
Profitability
This table compares Longeveron and VG Life Sciences' net margins, return on equity and return on assets.
Get Longeveron alerts:Net Margins | Return on Equity | Return on Assets | |
Longeveron | -1,408.17% | -58.68% | -49.93% |
VG Life Sciences | N/A | N/A | N/A |
Insider and Institutional Ownership
2.1% of Longeveron shares are held by institutional investors. 41.6% of Longeveron shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current recommendations and price targets for Longeveron and VG Life Sciences, as provided by MarketBeat.com.Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Longeveron | 0 | 0 | 2 | 0 | 3.00 |
VG Life Sciences | 0 | 0 | 0 | 0 | N/A |
Longeveron presently has a consensus price target of $13.25, indicating a potential upside of 231.95%.
Earnings & Valuation
This table compares Longeveron and VG Life Sciences' revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Longeveron | $1.31 million | 63.95 | -$17.05 million | ($0.89) | -4.48 |
VG Life Sciences | N/A | N/A | N/A | N/A | N/A |
VG Life Sciences has lower revenue, but higher earnings than Longeveron.
Risk and Volatility
Longeveron has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, VG Life Sciences has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500.
About Longeveron
(Get Rating)
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
About VG Life Sciences
(Get Rating)
VG Life Sciences, Inc. engages as a drug discovery and development company. It focuses on Targeted Peptide Technology (TPT), and Metabolic Disruption Technology (MDT). The TPT deals with HIV/AIDS. The MDT helps to fight cancers with solid tumors in situations where the cancer is resistant to the initial cancer drug therapy. The company was founded by Haig Keledjian in 1994 and is headquartered in New York, NY.
Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.
Longeveron (NASDAQ:LGVN – Get Rating) and VG Life Sciences (OTCMKTS:VGLS – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.
龍永隆(NASDAQ:LGVN-獲得評級)和 VG 生命科學(OTCMKTS:VGLS-獲得評級)都是小型股醫療公司,但哪些是優越的業務?我們將根據股息,收益,機構所有權,風險,估值,盈利能力和分析師建議的實力對兩家企業進行比較。
Profitability
盈利
This table compares Longeveron and VG Life Sciences' net margins, return on equity and return on assets.
本表比較長壽及 VG 生命科學的淨利潤率、股本回報率及資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Longeveron | -1,408.17% | -58.68% | -49.93% |
VG Life Sciences | N/A | N/A | N/A |
淨利潤 | 權益回報率 | 資產回報率 | |
龍日威 | -1,408.17% | -58.68% | -49.93% |
VG 生命科學 | N/A | N/A | N/A |
Insider and Institutional Ownership
內幕和機構所有權
2.1% of Longeveron shares are held by institutional investors. 41.6% of Longeveron shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
2.1% 的隆盛股份是由機構投資者持有。41.6% 的龍之股份由內部人士持有。強大的機構所有權表明,對沖基金,大型資金經理和捐贈基金認為,從長期來看,公司的表現將優於市場。
Analyst Recommendations
分析師推薦
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Longeveron | 0 | 0 | 2 | 0 | 3.00 |
VG Life Sciences | 0 | 0 | 0 | 0 | N/A |
銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
龍日威 | 0 | 0 | 2 | 0 | 3.00 |
VG 生命科學 | 0 | 0 | 0 | 0 | N/A |
Longeveron presently has a consensus price target of $13.25, indicating a potential upside of 231.95%.
龍之隆目前的一致價格目標為 13.25 美元,表明潛在的上行空間為 231.95%。
Earnings & Valuation
盈利及估值
This table compares Longeveron and VG Life Sciences' revenue, earnings per share and valuation.
此表格比較長壽和 VG 生命科學的收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Longeveron | $1.31 million | 63.95 | -$17.05 million | ($0.89) | -4.48 |
VG Life Sciences | N/A | N/A | N/A | N/A | N/A |
總收入 | 價格/銷售比率 | 淨收入 | 每股盈利 | 市盈比率 | |
龍日威 | 一百三十一萬元 | 63.95 | -一千七百零五萬美元 | (港幣 89 元) | -4.48 |
VG 生命科學 | N/A | N/A | N/A | N/A | N/A |
VG Life Sciences has lower revenue, but higher earnings than Longeveron.
VG 生命科學具有較低的收入,但收益比隆隆更高。
Risk and Volatility
風險及波動性
Longeveron has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, VG Life Sciences has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500.
龍之權的測試值為 0.65,這意味著其股價比標普 500 少 35% 的波動性。相比之下,VG 生命科學的測試版為 1.67,這意味著其股價的波動性比標普 500 大 67%。
About Longeveron
關於龍之隆
(Get Rating)
(取得評分)
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Lageveron Inc. 是一家臨床階段生物技術公司,開發針對老化相關和危及生命疾病的細胞療法。該公司的主要研究產品是 LOMECEL-B,這是一種基於細胞的治療產品,源自擴大文化的藥用信號傳導細胞,該細胞來自年輕健康成年捐贈者的骨髓。它正在針對各種適應症進行 1 期和 2 期臨床試驗,例如老化脆弱,阿爾茨海默氏病,代謝綜合徵,急性呼吸窘迫綜合徵和塑性減退左心綜合徵。該公司成立於 2014 年,總部設在佛羅里達州的邁阿密。
About VG Life Sciences
關於 VG 生命科學
(Get Rating)
(取得評分)
VG Life Sciences, Inc. engages as a drug discovery and development company. It focuses on Targeted Peptide Technology (TPT), and Metabolic Disruption Technology (MDT). The TPT deals with HIV/AIDS. The MDT helps to fight cancers with solid tumors in situations where the cancer is resistant to the initial cancer drug therapy. The company was founded by Haig Keledjian in 1994 and is headquartered in New York, NY.
VG 生命科學公司從事藥物發現和開發公司。它專注於目標肽技術(TPT)和代謝破壞技術(MDT)。TPT 處理艾滋病毒/艾滋病.MDT 有助於在癌症對初始癌症藥物治療有抵抗力的情況下對抗實體腫瘤的癌症。該公司由黑格克勒健於 1994 年成立,總部位於紐約州紐約。
Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.
接收龍日報的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收對 Linyveron 及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧